8.255
1.61%
-0.135
After Hours:
8.26
0.005
+0.06%
Nyxoah Sa stock is traded at $8.255, with a volume of 19,351.
It is down -1.61% in the last 24 hours and down -12.74% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$8.39
Open:
$8.39
24h Volume:
19,351
Relative Volume:
0.29
Market Cap:
$308.96M
Revenue:
$4.71M
Net Income/Loss:
$-46.77M
P/E Ratio:
-4.715
EPS:
-1.7508
Net Cash Flow:
$-60.34M
1W Performance:
+3.19%
1M Performance:
-12.74%
6M Performance:
-4.90%
1Y Performance:
+61.86%
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
8.255 | 308.96M | 4.71M | -46.77M | -60.34M | -1.6792 |
ISRG
Intuitive Surgical Inc
|
542.00 | 193.05B | 7.87B | 2.24B | 586.00M | 6.22 |
BDX
Becton Dickinson Co
|
221.90 | 64.77B | 20.18B | 1.71B | 3.07B | 5.94 |
ALC
Alcon Inc
|
88.85 | 43.95B | 9.76B | 1.16B | 665.00M | 2.34 |
RMD
Resmed Inc
|
249.02 | 36.58B | 4.81B | 1.11B | 1.35B | 7.55 |
WST
West Pharmaceutical Services Inc
|
325.68 | 23.63B | 2.88B | 499.60M | 321.60M | 6.74 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-31-23 | Initiated | H.C. Wainwright | Buy |
Jul-19-23 | Initiated | Robert W. Baird | Neutral |
Apr-21-22 | Initiated | Oppenheimer | Outperform |
Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Information on the Total Number of Voting Rights And Shares: Nyxoah - The Korea Bizwire
Information on the total number of voting rights and shares - GlobeNewswire
Objective long/short (NYXH) Report - Stock Traders Daily
Nyxoah (NASDAQ:NYXH) vs. Alpha Tau Medical (NASDAQ:DRTS) Head to Head Contrast - Defense World
Nyxoah to Present at Healthcare Conference Amidst Growth - TipRanks
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Nyxoah to Present Sleep Apnea Innovation at Piper Sandler Healthcare Conference | NYXH Stock News - StockTitan
Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Nyxoah Schedules Special Meeting to Vote on EIB Loan Agreement Terms | NYXH Stock News - StockTitan
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024: Nyxoah - The Korea Bizwire
Invitation to attend the special shareholders’ meeting of the Company to be held on December 19, 2024 - GlobeNewswire
Publication Relating to Transparency Notifications: Nyxoah - The Korea Bizwire
Nyxoah’s Voting Rights Shift with ResMed Stake - TipRanks
Publication relating to transparency notifications - GlobeNewswire
ResMed's Stake in Nyxoah Drops Below 5% Threshold in Latest Holdings Update | NYXH Stock News - StockTitan
Nyxoah S.A. (NASDAQ:NYXH) Short Interest Down 17.4% in October - MarketBeat
Nyxoah's SWOT analysis: sleep apnea device maker's stock poised for growth - Investing.com India
Nyxoah Third Quarter 2024 Earnings: €0.50 loss per share (vs €0.27 loss in 3Q 2023) - Simply Wall St
Nyxoah Reports Third Quarter Financial and Operating Results - Wahanariau
Nyxoah sales jump 30% to €1.3 million in Q3 2024 - Medical Buyer
Nyxoah SA Reports Growth Amid Clinical Advances - TipRanks
EQS-News: Nyxoah Reports Third Quarter Financial and Operating Results - sharewise
Nyxoah Eyes Strong US Launch Amid Financial Growth - TipRanks
Nyxoah S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nyxoah Reports Third Quarter Financial and Operating Results, Business Wires News - AsiaOne
(NYXH) Investment Report - Stock Traders Daily
Nyxoah SA (NYXH) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Nyxoah SA Announces CFO Changes - Marketscreener.com
Nyxoah participates in a conference call with Cantor Fitzgerald - TipRanks
Nyxoah Appoints John Landry as Chief Financial Officer - The Manila Times
Nyxoah Strengthens Leadership for U.S. and Global Expansion - TipRanks
Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Trend Tracker for (NYXH) - Stock Traders Daily
Publication relating to transparency notifications: Nyxoah - The Korea Bizwire
Transparency Notification: Vestal Point Capital’s Stake in Nyxoah - PanAsiaBiz
NYXHNyxoah SA Ordinary Shares Latest Stock News & Market Updates - StockTitan
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024, Business Wires News - AsiaOne
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 - The Manila Times
Nyxoah - Via Ritzau
Behind the Bell: Nyxoah SA - Nasdaq
Nyxoah raises $27M for US commercialization of sleep apnea technology - BioWorld Online
How To Trade (NYXH) - Stock Traders Daily
Nyxoah Shareholdings Shift: Hambrecht and BlackRock Update - TipRanks
Nyxoah (NASDAQ:NYXH) Price Target Cut to $17.00 - Defense World
Nyxoah shares price target cut by H.C. Wainwright - Investing.com India
HC Wainwright Lowers Nyxoah (NASDAQ:NYXH) Price Target to $17.00 - MarketBeat
Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference, Business Wires News - AsiaOne
Nyxoah price target lowered to $17 from $18 at H.C. Wainwright - TipRanks
Nyxoah Raises $27M Through US Healthcare Investor to Support Genio Launch - Sleep Review
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):